A detailed history of Loomis Sayles & CO L P transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Loomis Sayles & CO L P holds 329,744 shares of BMRN stock, worth $22.2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
329,744
Previous 331,502 0.53%
Holding current value
$22.2 Million
Previous $27.3 Million 15.08%
% of portfolio
0.03%
Previous 0.04%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$69.02 - $93.84 $121,337 - $164,970
-1,758 Reduced 0.53%
329,744 $23.2 Million
Q2 2024

Aug 13, 2024

BUY
$74.43 - $92.22 $24.7 Million - $30.6 Million
331,502 New
331,502 $27.3 Million
Q2 2023

Aug 11, 2023

SELL
$86.68 - $100.3 $10.5 Million - $12.1 Million
-121,050 Reduced 99.62%
465 $40,000
Q1 2023

May 11, 2023

SELL
$87.74 - $117.27 $4.09 Million - $5.47 Million
-46,607 Reduced 27.72%
121,515 $11.8 Million
Q4 2022

Feb 10, 2023

SELL
$80.93 - $108.63 $15.2 Million - $20.5 Million
-188,367 Reduced 52.84%
168,122 $17.4 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $2.13 Million - $2.52 Million
-25,949 Reduced 6.79%
356,489 $30.2 Million
Q2 2022

Aug 05, 2022

SELL
$71.48 - $86.85 $910,154 - $1.11 Million
-12,733 Reduced 3.22%
382,438 $31.7 Million
Q1 2022

May 13, 2022

SELL
$74.28 - $92.69 $4.29 Million - $5.35 Million
-57,743 Reduced 12.75%
395,171 $30.5 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $705,939 - $900,339
-9,843 Reduced 2.13%
452,914 $40 Million
Q3 2021

Nov 12, 2021

BUY
$74.77 - $85.47 $200,682 - $229,401
2,684 Added 0.58%
462,757 $35.8 Million
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $4.22 Million - $4.73 Million
-55,826 Reduced 10.82%
460,073 $38.4 Million
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $265,216 - $321,858
-3,549 Reduced 0.68%
515,899 $39 Million
Q4 2020

Feb 12, 2021

SELL
$72.61 - $90.2 $4.53 Million - $5.63 Million
-62,440 Reduced 10.73%
519,448 $45.6 Million
Q3 2020

Nov 12, 2020

SELL
$71.87 - $131.03 $2.24 Million - $4.08 Million
-31,175 Reduced 5.09%
581,888 $44.3 Million
Q2 2020

Aug 14, 2020

SELL
$79.55 - $124.22 $2.47 Million - $3.85 Million
-31,009 Reduced 4.81%
613,063 $75.6 Million
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $3.81 Million - $5.17 Million
-53,362 Reduced 7.65%
644,072 $54.4 Million
Q4 2019

Feb 14, 2020

SELL
$64.27 - $86.37 $8.47 Million - $11.4 Million
-131,710 Reduced 15.89%
697,434 $59 Million
Q3 2019

Nov 13, 2019

SELL
$67.4 - $85.11 $1.61 Million - $2.04 Million
-23,931 Reduced 2.81%
829,144 $55.9 Million
Q2 2019

Aug 14, 2019

SELL
$80.35 - $93.9 $360,048 - $420,765
-4,481 Reduced 0.52%
853,075 $73.1 Million
Q1 2019

May 15, 2019

BUY
$84.2 - $98.62 $871,891 - $1.02 Million
10,355 Added 1.22%
857,556 $76.2 Million
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $5.82 Million - $7.71 Million
-72,684 Reduced 7.9%
847,201 $72.1 Million
Q3 2018

Nov 13, 2018

SELL
$93.92 - $105.72 $2.01 Million - $2.26 Million
-21,407 Reduced 2.27%
919,885 $89.2 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $5.37 Million - $7 Million
70,654 Added 8.12%
941,292 $88.7 Million
Q1 2018

May 11, 2018

BUY
$77.67 - $92.63 $67.6 Million - $80.6 Million
870,638 New
870,638 $70.6 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.5B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.